Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MC-509
- Development stage
- Preclinical
- Lead developer
- ViroCure
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics
01
Overview
MC-509 is an experimental oncolytic virus therapy being developed by ViroCure Australia, in partnership with ViroCure Inc., for the treatment of colorectal cancer. Currently in the preclinical stage, MC-509 is designed to selectively infect and replicate within malignant cells, leading to direct tumor cell lysis. This process releases tumor-associated antigens and pathogen-associated molecular patterns (PAMPs), which are intended to stimulate a systemic anti-tumor immune response. The candidate leverages ViroCure's proprietary viral platform, which focuses on utilizing the natural oncolytic properties of specific viral strains to target solid tumors like colorectal cancer.
Beyond the preview
Go deeper on MC-509.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MC-509.